TOPOTECAN/IFOSFAMIDE THERAPY FOR RELAPSED/REFRACTORY PEDIATRIC SOLID TUMORS

被引：0
|
作者：
Sugiyama, Masanaka [1 ]
Arakawa, Ayumu [1 ,2 ]
Watanabe, Yuko [1 ]
Nakajima, Miho [1 ]
Tanimura, Kazuki [1 ]
Uchida, Eriko [1 ]
Tao, Kayoko [1 ]
Yoneda, Akihiro [3 ]
Kawai, Akira [4 ]
Ogawa, Chitose [1 ,2 ]
机构：
[1] Natl Canc Ctr, Dept Pediat Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan
[3] Natl Canc Ctr, Dept Pediat Surg Oncol, Tokyo, Japan
[4] Natl Canc Ctr, Dept Musculoskeletal Oncol & Rehabil, Tokyo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2024年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS7-5
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] Topotecan chemotherapy for refractory or relapsed hematological malignancies
    Wu, DP
    Tang, XW
    Sun, AN
    Fu, ZZ
    Ruan, CG
    BLOOD, 2002, 100 (11) : 262B - 262B
  • [42] The role of ifosfamide in the treatment of relapsed and refractory lymphoma
    Reiser, M
    Bredenfeld, H
    Engert, A
    Diehl, V
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 66 : 37 - 40
  • [43] A PHASE I STUDY OF NAB-PACLITAXEL COMBINED WITH GEMCITABINE FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS
    Metts, Jonathan
    Ginn, Kevin
    Cost, Carrye
    Froug, Brittani
    Watt, Amanda
    Schink, Melissa
    Senn, Stacy
    Cash, Thomas
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S319 - S320
  • [44] PHASE I STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS: A POETIC GROUP STUDY
    Manley, P.
    Trippett, T.
    Smith, A.
    Macy, M.
    Leary, S.
    Boklan, J.
    Cohen, K.
    Shen, L.
    Herzog, C.
    Veyrat-Follet, C.
    Zhang, J.
    Chi, S.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S157 - S158
  • [45] Phase I study of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed malignant tumors
    Rubie, H.
    Frappaz, D.
    Defachelles, A.
    Ndiaye, A.
    Dias, N.
    Aerts, I.
    Gentet, J.
    Djafari, L.
    Jaworski, M.
    Vassal, G.
    Geoerger, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Phase I study of combination topotecan and carboplatin in pediatric solid tumors
    Athale, UH
    Stewart, C
    Kuttesch, JF
    Moghrabi, A
    Meyer, W
    Pratt, C
    Gajjar, A
    Heideman, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 88 - 95
  • [47] Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.
    DuBois, Steven G.
    Weigel, Brenda
    Laetsch, Theodore Willis
    Macy, Margaret
    Levy, Donna Elise
    Mo, Gary
    Wright, Jennifer A.
    Mascarenhas, Leo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors
    Carlos Rodriguez-Galindo
    Kristine R. Crews
    Clinton F. Stewart
    Wayne Furman
    J. Carl Panetta
    Najat C. Daw
    Alvida Cain
    Ming Tan
    Peter H. Houghton
    Victor M. Santana
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 15 - 24
  • [49] Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors
    Rodriguez-Galindo, C
    Crews, KR
    Stewart, CF
    Furman, W
    Panetta, JC
    Daw, NC
    Cain, A
    Tan, M
    Houghton, PH
    Santana, VM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 15 - 24
  • [50] Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
    Reed, Damon R.
    Mascarenhas, Leo
    Manning, Kathleen
    Hale, Gregory A.
    Goldberg, John
    Gill, Jonathan
    Sandler, Eric
    Isakoff, Michael S.
    Smith, Tiffany
    Caracciolo, Jamie
    Lush, Richard M.
    Juan, Tzu-Hua
    Lee, Jae K.
    Neuger, Anthony M.
    Sullivan, Daniel M.
    CANCER MEDICINE, 2016, 5 (02): : 294 - 303
12345